Gyre Therapeutics Inc. (GYRE)
10.82
0.30 (2.85%)
At close: Jan 15, 2025, 3:41 PM
Company Description
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States.
In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application.
Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
Gyre Therapeutics Inc.
| Country | n/a |
| IPO Date | Apr 12, 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 593 |
| CEO | Dr. Han Ying Ph.D. |
Contact Details
Address: No Address available No city data available, | |
| Website | https://www.gyretx.com |
Stock Details
| Ticker Symbol | GYRE |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001124105 |
| CUSIP Number | n/a |
| ISIN Number | US4037831033 |
| Employer ID | 56-2020050 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Han Ying Ph.D. | Chief Executive Officer & Director |
| Ruoyu Chen | Chief Financial Officer |
| Weiguo Ye | Chief Operating Officer |
| Seline E. Miller CPA | Senior Vice President of Finance |
| Songjiang Ma | President & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 14, 2025 | 4 | Filing |
| Jan 10, 2025 | 4/A | [Amend] Filing |
| Jan 08, 2025 | 4 | Filing |
| Jan 07, 2025 | 4 | Filing |
| Jan 07, 2025 | 3 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 8-K | Current Report |
| Jan 02, 2025 | 4 | Filing |
| Dec 30, 2024 | 4 | Filing |
| Dec 26, 2024 | 4 | Filing |